Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Quest Pharmatech ( (TSE:QPT) ) is now available.
Quest PharmaTech Inc. has announced the conversion of its bonds in OQP Bio Inc. into shares of OQPBIOM Inc., making it the largest shareholder with a 26.25% stake. This strategic move strengthens Quest’s position in the cancer immunotherapy market, as OQPBIOM Inc. develops immunotherapeutic products for cancer treatment. The company plans to engage an independent valuator to assess the value of these shares for future financial statements.
More about Quest Pharmatech
Quest PharmaTech Inc. is a publicly traded Canadian biopharmaceutical company focused on developing products to enhance quality of life. It holds a significant ownership in OncoQuest Inc., which previously sold its immunotherapy technology to a Korean company, and OncoVent, a joint venture in China developing cancer immunotherapeutics. Quest is also advancing its proprietary MAb AR 9.6 for cancer treatment.
Average Trading Volume: 89,641
Technical Sentiment Signal: Hold
Current Market Cap: C$5.92M
Find detailed analytics on QPT stock on TipRanks’ Stock Analysis page.